U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07424833) titled 'A Study of APG-3288 in Relapsed/Refractory Blood Cancers' on Feb. 01.
Brief Summary: This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Hematological Malignancies
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL
Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Includi...